相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Paola Filipazzi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
Claudia A. Dumitru et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling
Srinivas Nagaraj et al.
CANCER RESEARCH (2012)
Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Alena Gros et al.
CLINICAL CANCER RESEARCH (2012)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Tillmann Michels et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wenshi Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Jianda Yuan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F. Gabitass et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Targeting myeloid regulatory cells in cancer by chemotherapeutic agents
Hiam Naiditch et al.
IMMUNOLOGIC RESEARCH (2011)
Myeloid derived suppressor cells in human diseases
Tim F. Greten et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Lukas Baitsch et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
Michele Del Vecchio et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab
Vernon K. Sondak et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
Virginia A. Pedicord et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Myeloid-Derived Suppressor Cells in Human Cancer
Srinivas Nagaraj et al.
CANCER JOURNAL (2010)
Immature Immunosuppressive CD14+HLA-DR-/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
Isabel Poschke et al.
CANCER RESEARCH (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
Bradley C. Carthon et al.
CLINICAL CANCER RESEARCH (2010)
The growing diversity and spectrum of action of myeloid-derived suppressor cells
Alberto Mantovani
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Treating Cancer by Targeting the Immune System
Patrick Hwu
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
Begona Comin-Anduix et al.
PLOS ONE (2010)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
Susanna Mandruzzato et al.
JOURNAL OF IMMUNOLOGY (2009)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients:: CD1c+ dendritic cell frequency predicts progression-free survival
Hester van Cruijsen et al.
CLINICAL CANCER RESEARCH (2008)
Reversal of Myeloid Cell - Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Sergei Kusmartsev et al.
CLINICAL CANCER RESEARCH (2008)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
G. Parmiani et al.
ANNALS OF ONCOLOGY (2007)
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
Noweeda Mirza et al.
CANCER RESEARCH (2006)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tcr ζ-chain downregulation:: Curtailing an excessive inflammatory immune response
M Baniyash
NATURE REVIEWS IMMUNOLOGY (2004)
Expression of CTLA-4 by human monocytes
XB Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2002)
分享论文
